Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press126410.17650/1726-9776-2007-0-2-56-60DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыZometa in therapy for bone metastases of prostate cancer during androgenic deprivation (Results of Russian multicenter study)Зомета в терапии рака предстательной железы с метастатическим поражением костей на фоне андрогенной депривации (результаты Российского многоцентрового исследования)KaryakinO. B.КарякинО. Б.
Russian Federation

Obninsk

Обнинск

MatveevB. P.МатвеевБ. П.
Russian Federation

Moscow

Москва

MatveevV. B.МатвеевВ. Б.
Russian Federation

Moscow

Москва

RusakovI. G.РусаковИ. Г.
Russian Federation

Moscow

Москва

LoranO. B.ЛоранО. Б.
Russian Federation

Moscow

Москва

VeliyevYe. I.ВелиевЕ. И.
Russian Federation

Moscow

Москва

ShaplyginL. V.ШаплыгинЛ. В.
Russian Federation

Moscow

Москва

BukharkinB. V.БухаркинБ. В.
Russian Federation

Moscow

Москва

BiryukovV. A.БирюковВ. А.
Russian Federation

Obninsk

Обнинск

MinayevaN. G.МинаеваН. Г.
Russian Federation

Obninsk

Обнинск

AtayevA. A.АтаевА. А.
Russian Federation

Moscow

Москва

ShelepovaV. M.ШелеповаВ. М.
Russian Federation

Moscow

Москва

KarelinM. I.КарелинМ. И.
Russian Federation

Saint Petersburg

Санкт-Петербург

ProkhorovD. G.ПрохоровД. Г.
Russian Federation

Saint Petersburg

Санкт-Петербург

KhrizmanYu. N.ХризманЮ. Н.
Russian Federation

Ufa

Уфа

ShakurovV. K.ШакуровВ. К.
Russian Federation

Ufa

Уфа

AbdrakhmanovE. F.АбдрахмановЭ. Ф.
Russian Federation

Kazan

Казань

ZhuravlevV. N.ЖуравлевВ. Н.
Russian Federation

Yekaterinburg

Екатеринбург

ZyryanovA. V.ЗыряновА. В.
Russian Federation

Yekaterinburg

Екатеринбург

MagerV. O.МагерВ. О.
Russian Federation

Yekaterinburg

Екатеринбург

KarnaukhP. A.КарнаухП. А.
Russian Federation

Chelyabinsk

Челябинск

Medical Radiology Research Center, Russian Academy of Medical SciencesМРНЦ РАМНN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesРОНЦ им.Н.Н.Блохина РАМНP.A. Herzen Moscow Research Oncological Institute, Ministry of Health and Social Development of the Russian FederationМНИОИ им. Герцена МЗ и СР РФDepartment of Urology and Surgical Andrology, Russian Medicаl Academy of Postgraduate EducationКафедра урологии и хирургической андрологии РМАПОDepartment of Urology and Surgical Andrology, Russian Medicаl Academy of Postgraduate EducationКафедра урологии и хирургической андрологии РМАПОN.N. Burdenko Main Military Clinical HospitalГВКГ им. Н.Н. БурденкоCentral Research Institute of Radiology, Ministry of Health and Social Development of the Russian FederationЦНИРИBashkir Republican Cancer DispensaryБашкирский республиканский ОДKazan Cancer DispensaryКОДDepartment of Urology, Urals State Medical AcademyКафедра урологии УГМАCancer Clinical Hospital No.1ОКБ №1Sverdlovsk Regional Cancer DispensaryСООДRegional Cancer DispensaryООД300620073256600303202003032020https://oncourology.abvpress.ru/oncur/article/view/1264

Introduction: Hormonal therapy is the method of choice in treating disseminated prostate cancer. Chronic androgenic suppression causes a reduction in bone mineral density. The most common complications of bone metastases are pathological fractures, spinal cord compression, pain, etc.

Methods: A multicenter study (11 clinics of Russia) assessing the efficacy of Zometa in preventing skeletal complications of bone metastases was conducted in 2004—2005. Zometa was administered intravenously at a dose of 4 mg every 3Р4 weeks with androgenic deprivation. Its objective effect was evaluated in 70 patients. Changes in bone mineral density were evaluated by densitometry.

Results: Complete pain relief was achieved in 73% of the patients; after therapy 86% of the patients had 0—1 WHO activity status score, 97% of the patients had no bone complications. The level of bone resorption marker β-Cross-Laps decreased to the normal values in 51% of the patients.

Conclusion: The study has provided an evidence of the efficacy of Zometa and the necessity of using this drug in complex therapy for bone metastases of prostate cancer.

Introduction: Hormonal therapy is the method of choice in treating disseminated prostate cancer. Chronic androgenic suppression causes a reduction in bone mineral density. The most common complications of bone metastases are pathological fractures, spinal cord compression, pain, etc.

Methods: A multicenter study (11 clinics of Russia) assessing the efficacy of Zometa in preventing skeletal complications of bone metastases was conducted in 2004—2005. Zometa was administered intravenously at a dose of 4 mg every 3Р4 weeks with androgenic deprivation. Its objective effect was evaluated in 70 patients. Changes in bone mineral density were evaluated by densitometry.

Results: Complete pain relief was achieved in 73% of the patients; after therapy 86% of the patients had 0—1 WHO activity status score, 97% of the patients had no bone complications. The level of bone resorption marker β-Cross-Laps decreased to the normal values in 51% of the patients.

Conclusion: The study has provided an evidence of the efficacy of Zometa and the necessity of using this drug in complex therapy for bone metastases of prostate cancer.

1. Матвеев Б.П. Клиническая онкоурология. 2003.Матвеев Б.П. Клиническая онкоурология. 2003.2. Давыдов М.И., Аксель Е.М. Злокачественные заболевания в России и странах СНГ в 2003 году. М.; 2004.Давыдов М.И., Аксель Е.М. Злокачественные заболевания в России и странах СНГ в 2003 году. М.; 2004.3. Coleman R.E. Metastatic bone disease:clinical features,pathophysiology and treatment strategies.Cancer Treat Rev 2001;27:165—76.Coleman R.E. Metastatic bone disease:clinical features,pathophysiology and treatment strategies.Cancer Treat Rev 2001;27:165—76.4. Cecchini M.G.,Wetterwald A., van der Pluijm G., Thalmann G.N. Molecular and Biological Mechanisms of Bone Metastasis. EAU Update Series 2005;3:214—26.Cecchini M.G.,Wetterwald A., van der Pluijm G., Thalmann G.N. Molecular and Biological Mechanisms of Bone Metastasis. EAU Update Series 2005;3:214—26.5. Bogdanos J., Karamanolakis D., Tenta R. et al. Endocrine/paracrine/autocrine survival factor activity of bone micro-environment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.Endocr Relat Cancer 2003;10(2):279—89.Bogdanos J., Karamanolakis D., Tenta R. et al. Endocrine/paracrine/autocrine survival factor activity of bone micro-environment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.Endocr Relat Cancer 2003;10(2):279—89.6. Saad F., Colerman R.E., Cook R. et al. Predictors of clinical outcome in patients with prostate cancer and bone metastases:prognostic significance of fractures and bone markers. Eur Urol Suppl 2006;5(2):55.Saad F., Colerman R.E., Cook R. et al. Predictors of clinical outcome in patients with prostate cancer and bone metastases:prognostic significance of fractures and bone markers. Eur Urol Suppl 2006;5(2):55.7. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19(10):80—100.Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19(10):80—100.8. Berruti A., Dogliotti L., Tucci M. et al. Metabolic bone disease induced by prostate cancer:rationale for the use of bisphosphonates. J Urology 2001;166(6):2023—31.Berruti A., Dogliotti L., Tucci M. et al. Metabolic bone disease induced by prostate cancer:rationale for the use of bisphosphonates. J Urology 2001;166(6):2023—31.9. Rosen L.S., Gordon D., Kaminski M. et al. Long-term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complication in patient with advanced multiple mieloma or breast carcinoma. Cancer 2003;98:1735—44.Rosen L.S., Gordon D., Kaminski M. et al. Long-term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complication in patient with advanced multiple mieloma or breast carcinoma. Cancer 2003;98:1735—44.10. Saad F., Gleason D.M., Murray R. et al.; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zolendronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11): 879—82.Saad F., Gleason D.M., Murray R. et al.; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zolendronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11): 879—82.11. Saad F., Gleason D.M., Murray R. et al.; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zolendronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458—68.Saad F., Gleason D.M., Murray R. et al.; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zolendronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458—68.12. Матвеев Б.П., Карякин О.Б., Матвеев В.Б. и др. Зомета в лечении больных распространенным раком предстательной железы (Результаты Российского многоцентрового исследования). Соврем онкол 2004;6(3).Матвеев Б.П., Карякин О.Б., Матвеев В.Б. и др. Зомета в лечении больных распространенным раком предстательной железы (Результаты Российского многоцентрового исследования). Соврем онкол 2004;6(3).13. Costa L., Demers L.M., Gouveia-Oliveira A. et al. Prospective evaluation of the peptide-bound collagen type I crosslinks N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850—6.Costa L., Demers L.M., Gouveia-Oliveira A. et al. Prospective evaluation of the peptide-bound collagen type I crosslinks N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850—6.